EMMPRIN, an upstream regulator of MMPs, in CNS biology

Matrix Biol. 2015 May-Jul:44-46:138-46. doi: 10.1016/j.matbio.2015.01.018. Epub 2015 Jan 31.

Abstract

Matrix metalloproteinases (MMPs) are engaged in pathologies associated with infections, tumors, autoimmune disorders and neurological dysfunctions. With the identification of an upstream regulator of MMPs, EMMPRIN (Extracellular matrix metalloproteinase inducer, CD147), it is relevant to address if EMMPRIN plays a role in the pathology of central nervous system (CNS) diseases. This would enable the possibility of a more upstream and effective therapeutic target. Indeed, conditions including gliomas, Alzheimer's disease (AD), multiple sclerosis (MS), and other insults such as hypoxia/ischemia show elevated levels of EMMPRIN which correlate with MMP production. In contrast, given EMMPRIN's role in CNS homeostasis with respect to regulation of monocarboxylate transporters (MCTs) and interactions with adhesion molecules including integrins, we need to consider that EMMPRIN may also serve important regulatory or protective functions. This review summarizes the current understanding of EMMPRIN's involvement in CNS homeostasis, its possible roles in escalating or reducing neural injury, and the mechanisms of EMMPRIN including and apart from MMP induction.

Keywords: CD147; Extracellular matrix; Inflammation; MMP inducer; Multiple sclerosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Basigin / drug effects
  • Basigin / metabolism*
  • Cell Adhesion Molecules / metabolism
  • Central Nervous System / metabolism*
  • Central Nervous System / pathology
  • Gene Expression Regulation, Enzymologic
  • Homeostasis
  • Humans
  • Matrix Metalloproteinases / metabolism*
  • Molecular Targeted Therapy
  • Monocarboxylic Acid Transporters / metabolism

Substances

  • BSG protein, human
  • Cell Adhesion Molecules
  • Monocarboxylic Acid Transporters
  • Basigin
  • Matrix Metalloproteinases